Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:03 2026-03-13 EDT			5-day change	1st Jan Change
219.68 ^USD	-2.52%		-4.53%	-3.86%

03-10	AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM
03-09	AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing	RE

Press Releases

03-09	AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults	PR
03-04	ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS	PR
03-03	AbbVie to Present at the Leerink Partners Global Healthcare Conference	PR
03-02	AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease	PR
02-24	AbbVie to Present at the TD Cowen 46th Annual Health Care Conference	PR
02-23	AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States	PR
02-20	U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)	PR
02-19	AbbVie Declares Quarterly Dividend	PR
02-04	AbbVie : Pipeline Update (ec207e)	PU
02-04	AbbVie : ABBV 4Q25 Press Release Final	PU
02-04	AbbVie: Q4 Earnings Snapshot	AQ
02-04	AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results	PR
02-03	Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program	PR
02-03	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo	PR
01-30	AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships	AQ
01-29	AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships	PR
01-28	Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine	PR
01-19	AbbVie Announces Topline Results for Epcoritamab (DuoBody(R) CD3xCD20) from Phase 3 EPCORE(R) DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	AQ
01-16	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	PR
01-12	AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans	PR
01-12	AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors	PR
01-12	West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie	PR
01-07	AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call	PR
01-06	MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus	AQ
01-05	AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference	PR